What are the outcomes of radical prostatectomy for high-risk prostate cancer?

Urology

Volumn 76, Issue 3, 2010, Pages 710-714

  Loeb, Stacy ^a   Schaeffer, Edward M ^a   Trock, Bruce J ^a   Epstein, Jonathan I ^a   Humphreys, Elizabeth B ^a   Walsh, Patrick C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL TIME; TREATMENT OUTCOME; MIDDLE AGED; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TIME;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953716767     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.014     Document Type: Article

References (22)

1. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
2. C.T. Nguyen, A.M. Reuther, and A.J. Stephenson The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival J Urol 181 2009 75 80
3. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106 2131 (Pubitemid 46726449)
4. M.V. Meng, E.P. Elkin, and D.M. Latini Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE) J Urol 173 2005 1557 1561
5. T.D. Denberg, L.M. Glode, and J.F. Steiner Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma BJU Int 98 2006 335 340
6. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
7. A.V. D'Amico, J. Manola, and M. Loffredo 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827
8. M.E. Allaf, G.S. Palapattu, and B.J. Trock Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer J Urol 172 2004 1840 1844
9. R.J. Kumar, A. Barqawi, and E.D. Crawford Preventing and treating the complications of hormone therapy Curr Urol Rep 6 2005 217 223
10. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
11. S.J. Freedland, A.W. Partin, and E.B. Humphreys Radical prostatectomy for clinical stage T3a disease Cancer 109 2007 1273 1278
12. A. Magheli, S. Rais-Bahrami, and H.J. Peck Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy J Urol 178 2007 1311 1315
13. P.J. Bastian, M.L. Gonzalgo, and W.J. Aronson Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8-10 Cancer 107 2006 1265 1272
14. S.A. Boorjian, R.J. Karnes, and L.J. Rangel Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy J Urol. 179 2008 1354 1360 Discussion:1360-1361
15. S. Loeb, N.D. Smith, and K.A. Roehl Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer Urology 69 2007 1170 1175
16. E.A. Klein, F.J. Bianco, and A.M. Serio Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories J Urol 179 2008 2212 2216 [discussion: 2216-2217]
17. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
18. T.H. Van der Kwast, M. Bolla, and H. Van Poppel Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy EORTC:22911 J Clin Oncol 25 2007 4178 4186
19. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 18 2009 2924 2930
20. C.J. Kane, J.C. Presti Jr., and C.L. Amling Changing nature of high risk patients undergoing radical prostatectomy J Urol 177 2007 113 117
21. O. Yossepowitch, S.E. Eggener, and F.J. Bianco Jr. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods J Urol 178 2007 493 499 [discussion: 499]
22. O. Yossepowitch, S.E. Eggener, and A.M. Serio Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy Eur Urol 53 2008 950 959